FOST Switch
Research type
Research Study
Full title
Evaluating efficacy and safety of switching a boosted protease inhibitor to fostemsavir in PLWH with limited therapeutic options
IRAS ID
1007532
Contact name
Debbie Roberts
Contact email
Sponsor organisation
NEAT ID
Research summary
This trial is to look at how effective and safe the recently approved HIV-1 medicine, fostemsavir (trade name: Rukobia) is when it is used in a routine clinical setting for the treatment of people living with HIV-1 for which other HIV medicine have not been effective and who now have few treatment options left. The research will be conducted at hospitals in the UK and Italy and patients will be treated for 48 weeks (with a 30 day follow up afterwards).
REC name
London - Hampstead Research Ethics Committee
REC reference
23/LO/0436
Date of REC Opinion
4 Sep 2023
REC opinion
Further Information Favourable Opinion